IXICO plc Announces two new biopharmaceutical contracts (8593W)

TIDMIXI

RNS Number : 8593W

IXICO plc

24 April 2019

24 April 2019

IXICO plc

("IXICO" or the "Company")

IXICO announces two new biopharmaceutical contracts

Providing specialist imaging clinical trials services for rare neurological diseases

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces that it has signed contracts with two biopharmaceutical companies to provide its technology-enabled imaging services to support an early phase study in Huntington's Disease (HD) and a phase 3 study in another rare neurological disease. The contracts are both the first to be signed with these clients.

As the selected imaging analysis partner for these studies, IXICO will utilise its data analytics expertise, developed over many years of working in the field, to provide critical insights which will support the evaluation of drug safety and efficacy. Study planning and site set-up activities are due to start imminently, contributing revenues for 2019 and into future periods.

The HD contract has a total value of approximately GBP2.0 million, which will be delivered over a seven-year term. HD is a rare genetic neurodegenerative disorder that affects movement, cognition and behaviour. This is an area of significant unmet medical need as there are currently no effective marketed treatments.

With 12 years' experience in HD studies and data analytics, IXICO is an established industry leader having supported early observational studies led by academic centres in Europe and North America, which characterised the progression of the disease. Since then IXICO has been successful in providing its clinical trial services to pharmaceutical and biopharmaceutical companies working in this important area of clinical development.

The second contract is with a company undergoing a phase 3 study in another rare neurological disease. This is initially a start-up agreement to enable IXICO to begin to deploy its services to the study which anticipates recruiting patients in June 2019. A contract for the full study is expected to be completed in the coming months.

Giulio Cerroni, Chief Executive Officer of IXICO, commented:

"Today's announcement follows multiple recent new contracts in Huntington's disease and builds on IXICO's strong track record and growing momentum in providing neuroimaging data analytics to important clinical research programmes in underserved neurodegenerative and rare neurological diseases. The field of rare neurological disease research is rapidly advancing and our continued success in winning new business in this area demonstrates the confidence that our clients have in our scientific and technical expertise to support their expanding clinical development programmes."

For further information please contact:

 
 IXICO plc                                         [phone] 
 Giulio Cerroni, Chief Executive Officer 
 
 Cenkos Securities PLC (Nominated adviser 
  and sole broker)                                 [phone] 
 Giles Balleny / Max Gould (Corporate Finance) 
 Michael F Johnson / Russell Kerr (Sales) 
 
 Optimum Strategic Communications                  [phone] 
 Mary Clark / Anne Marieke Ezendam / Supriya 
  Mathur 
 [e-mail] 
 

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.

IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.

More information is available on www.IXICO.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCLLFLRSDIVFIA

(END) Dow Jones Newswires

April 24, 2019 02:00 ET (06:00 GMT)